© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Novel GLP-1 RA for Obesity Shows Promise in Early Phase 1 Trial
September 09, 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
CDC COVID-19 Vaccine Bridge Access Program Ends 4 Months Earlier than Planned
September 09, 2024
The Bridge Access Program allowed Americans who are uninsured or underinsured to receive COVID-19 vaccination at not cost and was ended abruptly last month.
Efsitora Alfa, Eli Lilly’s Once Weekly Insulin, Has Positive Topline Results in Two Trials
September 06, 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
The CRF Pathway Interrupted: Potential to Transform CAH Care
September 03, 2024
A therapeutic strategy that reduces ACTH-driven androgen excess through a glucocorticoid-independent pathway could significantly improve treatment and patient QoL.
US Dementia-Related Mortality Rising with Greatest Impact Among Black Adults, Women, and in Nonurban Areas
August 26, 2024
The increase in the adult population with and at risk for dementia portends future burden among groups and communities with the fewest resources to cope.
CPAP Therapy May Reduce Hypertensive Disorders of Pregnancy by More than 30%: Meta-Analysis
August 26, 2024
Obstructive sleep apnea during pregnancy increases risk for gestational hypertension and preeclampsia; CPAP therapy may lower risk significantly.
Combination Statin Plus Ezetimibe More Effective than High-Dose Statin to Reduce LDL-C in People with ASCVD
August 23, 2024
In secondary CVD prevention, low/moderate-dose statins plus ezetimibe were superior to high-dose statin for reducing biomarkers, myalgias but did not reduce MACE.
Alternative Lung Cancer Screening Criteria Expand Eligible Population vs USPSTF Guidance
August 21, 2024
Simple criteria for lung cancer screening identified more people who would highly benefit, including more from racial/ethnic minority groups.
Tirzepatide Cuts Risk of Progression to T2D by 94% Over 3 Years in Adults with Obesity, Overweight
August 20, 2024
Results of the 3-year SURMOUNT-1 study reflect the longest trial to date of tirzepatide in adults with overweight/obesity and risk for developing T2D.
PTSD May be a Modifiable Risk Factor for Poor T2D Outcomes
August 20, 2024
Younger US veterans with PTSD and type 2 diabetes who no longer met criteria for PTSD were less likely to initiate insulin and had reduced odds of mortality.